Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ABBV NYSE:ANTM NYSE:JNJ NYSE:NVS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$198.10-0.4%$189.13$163.81▼$218.66$349.96B0.56.79 million shs4.10 million shsANTMAnthem$0.00$355.43▼$533.68$116.34BN/A1.21 million shs1.27 million shsJNJJohnson & Johnson$173.40+1.1%$158.89$140.68▼$173.96$417.61B0.419.09 million shs7.69 million shsNVSNovartis$116.80+0.8%$118.17$96.06▼$124.83$246.73B0.622.01 million shs1.59 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie+1.22%+5.15%+4.83%+7.85%+6.00%ANTMAnthem0.00%0.00%0.00%0.00%0.00%JNJJohnson & Johnson+0.40%+4.03%+10.05%+11.32%+7.87%NVSNovartis+2.06%+1.99%-4.85%+6.63%+4.26%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABBVAbbVie4.6681 of 5 stars2.44.03.33.93.92.51.3ANTMAnthemN/AN/AN/AN/AN/AN/AN/AN/AJNJJohnson & Johnson4.6829 of 5 stars2.33.04.23.94.11.71.9NVSNovartis1.7878 of 5 stars1.03.02.50.03.40.01.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABBVAbbVie 2.93Moderate Buy$214.438.24% UpsideANTMAnthem 0.00N/AN/AN/AJNJJohnson & Johnson 2.65Moderate Buy$174.500.63% UpsideNVSNovartis 2.09Hold$123.505.74% UpsideCurrent Analyst Ratings BreakdownLatest ANTM, JNJ, ABBV, and NVS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/8/2025NVSNovartisMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeUnderweight ➝ Equal Weight$123.008/7/2025ABBVAbbVieDaiwa AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy8/7/2025ABBVAbbVieDaiwa Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Outperform$214.008/1/2025ABBVAbbVieMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$250.00 ➝ $255.008/1/2025ABBVAbbVieGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$216.00 ➝ $227.008/1/2025ABBVAbbVieRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$227.00 ➝ $236.007/23/2025JNJJohnson & JohnsonErste Group BankSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy7/17/2025JNJJohnson & JohnsonPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight7/17/2025JNJJohnson & JohnsonBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$165.00 ➝ $176.007/17/2025JNJJohnson & JohnsonRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$181.00 ➝ $185.007/17/2025JNJJohnson & JohnsonUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$180.00 ➝ $190.00(Data available from 8/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABBVAbbVie$56.33B6.21$15.06 per share13.15($0.08) per share-2,476.25ANTMAnthemN/AN/AN/AN/AN/AN/AJNJJohnson & Johnson$90.63B4.61$13.34 per share13.00$32.58 per share5.32NVSNovartis$50.32B4.90$11.01 per share10.61$19.91 per share5.87Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABBVAbbVie$4.28B$2.1094.3314.171.266.45%699.66%13.64%N/AANTMAnthemN/A$32.5414.83N/AN/AN/AN/AN/AN/AJNJJohnson & Johnson$14.07B$9.3518.5515.662.1725.00%32.49%13.00%10/21/2025 (Estimated)NVSNovartis$11.94B$6.8717.0013.261.6025.64%41.08%16.83%N/ALatest ANTM, JNJ, ABBV, and NVS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/31/2025Q2 2025ABBVAbbVie$3.24$2.97-$0.27$0.52$14.93 billion$15.42 billion7/17/2025Q2 2025NVSNovartis$2.38$2.42+$0.04$2.06$13.94 billion$14.05 billion7/16/2025Q2 2025JNJJohnson & Johnson$2.68$2.77+$0.09$2.29$22.85 billion$23.74 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABBVAbbVie$6.563.31%N/A312.38%53 YearsANTMAnthem$5.121.06%N/A15.73%N/AJNJJohnson & Johnson$5.203.00%N/A55.61%64 YearsNVSNovartis$2.602.23%N/A37.85%N/ALatest ANTM, JNJ, ABBV, and NVS DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date7/16/2025JNJJohnson & Johnsonquarterly$1.303.35%8/26/20258/26/20259/9/20256/20/2025ABBVAbbViequarterly$1.643.54%7/15/20257/15/20258/15/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABBVAbbVie44.140.740.64ANTMAnthemN/AN/AN/AJNJJohnson & Johnson0.501.010.76NVSNovartis0.530.820.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABBVAbbVie70.23%ANTMAnthemN/AJNJJohnson & Johnson69.55%NVSNovartis13.12%Insider OwnershipCompanyInsider OwnershipABBVAbbVie0.25%ANTMAnthemN/AJNJJohnson & Johnson0.16%NVSNovartis0.01%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABBVAbbVie55,0001.77 billion1.76 billionOptionableANTMAnthemN/A241.09 millionN/AOptionableJNJJohnson & Johnson138,1002.41 billion2.40 billionOptionableNVSNovartis75,8832.11 billion2.11 billionOptionableANTM, JNJ, ABBV, and NVS HeadlinesRecent News About These CompaniesEuropean shares mixed as investors eye corporate results, trade talksAugust 8 at 12:11 PM | msn.comNovartis AG (NYSE:NVS) Shares Sold by Foresight Global Investors Inc.August 8 at 7:34 AM | marketbeat.comPrimecap Management Co. CA Sells 642,160 Shares of Novartis AG (NYSE:NVS)August 7 at 6:36 AM | marketbeat.comExencial Wealth Advisors LLC Sells 8,128 Shares of Novartis AG (NYSE:NVS)August 7 at 6:35 AM | marketbeat.comBlair William & Co. IL Sells 3,730 Shares of Novartis AG (NYSE:NVS)August 7 at 5:55 AM | marketbeat.comCommonwealth Equity Services LLC Lowers Stock Position in Novartis AG (NYSE:NVS)August 7 at 4:15 AM | marketbeat.comAvidity Biosciences jumps on report of Novartis takeover approachAugust 6 at 7:06 PM | msn.comAvidity Biosciences stock soars on Novartis takeover approach reportAugust 6 at 7:06 PM | finance.yahoo.comNovartis Reportedly Eyeing To Acquire Avidity Biosciences: But Retail Expects Management To Sell Only At Significant PremiumAugust 6 at 7:06 PM | msn.comAvidity Biosciences Rockets As Novartis Reportedly Mulls A Takeover DealAugust 6 at 7:06 PM | msn.comNovartis weighs deal for biotech Avidity Biosciences, FT reportsAugust 6 at 11:41 AM | reuters.comScotia Capital Inc. Cuts Stake in Novartis AG (NYSE:NVS)August 5 at 4:58 AM | marketbeat.comPNC Financial Services Group Inc. Acquires 7,791 Shares of Novartis AG (NYSE:NVS)August 5 at 4:47 AM | marketbeat.comQ1 Earnings Forecast for Novartis Issued By Zacks ResearchAugust 5 at 2:51 AM | americanbankingnews.comBernstein Maintains a Buy Rating on Novartis (NVS), Sets a CHF108 PTAugust 4, 2025 | msn.comNewEdge Wealth LLC Has $48.14 Million Stock Position in Novartis AG (NYSE:NVS)August 4, 2025 | marketbeat.comBanco Santander S.A. Acquires 4,615 Shares of Novartis AG (NYSE:NVS)August 4, 2025 | marketbeat.comNovartis AG (NYSE:NVS) Shares Sold by US Bancorp DEAugust 4, 2025 | marketbeat.comIFG Advisory LLC Has $1.44 Million Stake in Novartis AG (NYSE:NVS)August 4, 2025 | marketbeat.comCommerce Bank Purchases 2,581 Shares of Novartis AG (NYSE:NVS)August 4, 2025 | marketbeat.comBayforest Capital Ltd Sells 2,522 Shares of Novartis AG (NYSE:NVS)August 4, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Short Squeeze Candidates With Big Catalysts on the HorizonBy Dan Schmidt | July 25, 2025View 3 Short Squeeze Candidates With Big Catalysts on the HorizonWhy the American Eagle Stock Rally Isn't Just Speculation By Gabriel Osorio-Mazilli | July 28, 2025View Why the American Eagle Stock Rally Isn't Just Speculation Want Steady Income? 3 Top Dividend Stocks for July 2025By Chris Markoch | July 17, 2025View Want Steady Income? 3 Top Dividend Stocks for July 2025AbbVie Stock Eyes Breakout as Pipeline and Profits GrowBy Chris Markoch | July 31, 2025View AbbVie Stock Eyes Breakout as Pipeline and Profits GrowJNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is NowBy Thomas Hughes | July 16, 2025View JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is NowANTM, JNJ, ABBV, and NVS Company DescriptionsAbbVie NYSE:ABBV$198.10 -0.76 (-0.38%) Closing price 03:59 PM EasternExtended Trading$198.26 +0.16 (+0.08%) As of 06:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.Anthem NYSE:ANTMElevance Health, Inc. operates as a health company, which engages in improving lives and communities, and making healthcare simpler. The firm supports consumers, families, and communities across the entire care journeyconnecting them to the care, support, and resources they need to lead healthier lives. It offers health plans and clinical, behavioral, pharmacy, and complex-care solutions which promote whole health. The company was founded in 1944 and is headquartered in Indianapolis, IN.Johnson & Johnson NYSE:JNJ$173.40 +1.87 (+1.09%) Closing price 03:59 PM EasternExtended Trading$173.72 +0.31 (+0.18%) As of 06:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.Novartis NYSE:NVS$116.80 +0.88 (+0.76%) Closing price 03:59 PM EasternExtended Trading$118.32 +1.52 (+1.30%) As of 06:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles Down DraftKings Posts Record Quarter, Eyes Profitability Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
